Madrigal Pharmaceuticals, Inc.
Clinical trials sponsored by Madrigal Pharmaceuticals, Inc., explained in plain language.
-
New pill shows promise in reducing liver fat in NASH patients
Disease control CompletedThis study tested an experimental drug called MGL-3196 in 125 adults with non-alcoholic steatohepatitis (NASH), a serious liver disease caused by fat buildup. The goal was to see if the drug could reduce liver fat compared to a placebo over 12 weeks. Participants took a daily pil…
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New pill shows promise for inherited high cholesterol
Disease control CompletedThis study tested an experimental drug called MGL-3196 in 116 adults with a genetic condition that causes very high cholesterol (heterozygous familial hypercholesterolemia). The main goal was to see if the drug could lower 'bad' LDL cholesterol more than a placebo over 12 weeks. …
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Kidney drug study checks safety of resmetirom
Knowledge-focused CompletedThis study looked at how the drug resmetirom is processed in people with severe kidney impairment compared to healthy people. 28 participants took 100 mg of resmetirom daily for 6 days. The goal was to measure drug levels in the blood and check for side effects, helping doctors u…
Phase: PHASE1 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:05 UTC